Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEAL study of albumin in hepatic encephalopathy
NCT03585257Phase 2Completed
- Sponsor
- Richmond VA Medical Center
- Start
- Jun 2018
- Primary completion
- Feb 2022
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatic encephalopathy (HE) comparing Albumin Arm with Placebo Arm (2 arms). Primary endpoints: Psychometric Hepatic Encephalopathy Score at 5 weeks and Minimal Hepatic Encephalopathy Reversal at 5 weeks. Started Jun 2018; status: completed.
02
Drugs
albumin (human)
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT03585257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03585257.